What is Tissue Analytics?
Tissue Analytics, Inc., established in 2014 and headquartered in Baltimore, Maryland, with a satellite office in Kansas City, Missouri, develops cutting-edge artificial intelligence and machine learning solutions. Their platform leverages computer vision to enhance documentation workflows and improve the quality of data within electronic medical records (EMR). The company's wound management software is designed for seamless integration with leading EMR systems such as Epic, Cerner, and Allscripts, positioning it as a key player in optimizing clinical efficiency and data accuracy for clinicians, industry stakeholders, and researchers across various therapeutic areas.
How much funding has Tissue Analytics raised?
Tissue Analytics has raised a total of $7.7M across 3 funding rounds:
Angel/Seed
$750K
Debt
$1.9M
Series A
$5M
Angel/Seed (2015): $750K with participation from DreamIt Health and Tencent
Debt (2016): $1.9M, investors not publicly disclosed
Series A (2018): $5M supported by Tencent, Intermountain Health, Penn Medicine, Dreamit Ventures, Molnlycke Health Care, and DigiTx Partners
Key Investors in Tissue Analytics
Tencent
Tencent Holdings Limited is a global technology conglomerate providing internet and mobile services, including online gaming, social media, and digital content. Their investment in Tissue Analytics suggests a strategic interest in the intersection of technology and healthcare data analytics.
Dreamit Ventures
Dreamit Ventures is an early-stage venture capital firm that invests in transformative technology companies. Their participation indicates a belief in Tissue Analytics' innovative approach to AI in healthcare.
Molnlycke Health Care
Molnlycke Health Care is a global medical products company specializing in wound care and surgical solutions. Their investment likely signifies a strategic partnership aimed at integrating advanced analytics into their existing healthcare product ecosystem.
What's next for Tissue Analytics?
With the recent major strategic investment, Tissue Analytics is poised to accelerate its development and market penetration. The substantial enterprise-level funding suggests a focus on scaling operations, expanding its technological capabilities, and potentially broadening its reach into new therapy areas or geographical markets. This strategic backing will likely enable the company to further refine its AI algorithms, enhance its SMART on FHIR integrations, and solidify its position as a leader in AI-driven healthcare documentation solutions, aiming to improve patient care through better data quality and optimized workflows.
See full Tissue Analytics company page
